– Alimentiv and Summit Clinical Research announce collaboration to promote clinical trials of non-alcoholic steatohepatitis (NASH)
LONDON, Nov. 3, 2022 /PRNewswire/ — Alimentiv Inc. (“Alimentiv”) and Summit Clinical Research, LLC (“Summit”) today announced a strategic alliance to advance drug development programs for non-alcoholic steatohepatitis ( NASH) faster and more efficiently. NASH is a growing global epidemic with no approved treatments. There are more than 100 drugs in clinical development (Fraile et al., 2021). Current challenges include optimizing endpoint evaluation, minimizing detection failures, and improving recruitment rates for this often asymptomatic disease.
Summit and Alimentiv have complementary skills and experience, and this collaboration will enhance clinical trial delivery at NASH. Summit, a leading Integrated Research Organization focused on driving recruitment and providing high-quality data through its network of sites, will work together with Alimentiv, a leading global provider of imaging and clinical trial management focused on gastroenterology ( GI), including liver biopsy evaluation, with a commitment to drive drug development in collaboration with its pharmaceutical, biotech and academic sponsors.
“Collaborating with Summit enables us to deliver on our promise to transform human health for NASH patients by driving the growing number of NASH compounds through the development pipeline faster and more efficiently,” said Hershell Thompson, director of clinical solutions of Alimentiv.
“Summit has deep interests in providing innovative support for the efficient execution of clinical trials in the area of NASH. Through this collaboration with Alimentiv, we are able to further this goal for trial sponsors and participating sites,” said Gail Hinkson, Director Overview of Summit Clinical Research.
This strategic alliance will facilitate Alimentiv and Summit’s continued leadership in GI clinical trials through better clinical trial design, faster and more efficient recruitment, reduced screen failure rates, improved patient experience, and trained teams that oversee all aspects of the trial.
About non-alcoholic steatohepatitis
Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD), characterized by chronic inflammation and accumulation of fat in the liver. Affecting some 35 million people worldwide, NASH is the most common chronic liver condition in Western populations, and the number of patients continues to rise. Untreated NASH can lead to cirrhosis and liver cancer. The market for NASH therapies is expected to grow to $27.2 billion by 2029. Despite unmet clinical need and attractive commercial opportunity, there are currently no FDA-approved therapies for this disease. Several therapeutic agents targeting different metabolic pathways are currently in clinical development.
About Alimentiv Inc.
Alimentiv is a global gastroenterology-focused contract research organization (CRO) providing clinical trials, central imaging management, precision medicine, and real-world testing services to the pharmaceutical and biotech industries. Headquartered in London, Ontario, Alimentiv employs more than 500 people at its operations in Canada, the United States, Europe, Asia-Pacific and Latin America. The organization’s unique model combines the efforts of internationally recognized academic researchers and operational experts to deliver integrated solutions to clients. Over the past 20 years, Alimentiv has become a recognized expert in clinical trial design, central imaging management solutions, outcome measurement development, and precision medicine for GI drug development. Today, Alimentiv provides services in more than 50 countries worldwide, collaborates with leading universities and academic institutions around the world, and works with many leading pharmaceutical and biotechnology organizations to bring new and improved treatment options to patients. Alimentiv is committed to investing in medical research and development, focusing on identifying barriers to drug development and seeking solutions that promote GI research. Research findings are put into practice in an efficient clinical trial methodology for clients that aligns with emerging regulatory standards. In collaboration with leading experts, Alimentiv has pioneered the development, validation and standardization of technology and outcome measures, shaping the evolving clinical trial landscape for multiple indications and delivering meaningful long-term consequences for patients, their treatment and society. For more information visit: www.alimentiv.com
Acerca de Summit Clinical Research, LLC
Summit is a leading integrated research organization focused on non-alcoholic steatohepatitis (NASH) clinical trials. Through an innovative approach and use of disruptive technologies, Summit offers a full spectrum of site enrichment and study enrollment services to sites and scientific expertise to sponsors. Headquartered in San Antonio, Texas, Summit brings together more than 100 experienced clinical trial sites in the United States, Europe, and Latin America to execute clinical trials quickly and with high-quality data. For more information visit https://summitclinicalresearch.com/
Contact: Fern Livingstone, Tel: 519.639.3205, Email: fern.livingstone@alimentiv.com
Photo – link
View original content: enlace
